- Minaris and Genetix Biotherapeutics have expanded their manufacturing partnership to increase commercial-scale production of LYFGENIA, an FDA-approved gene therapy for sickle cell disease.
- The expansion includes process and operational improvements to raise output, reduce turnaround times, and support long-term commercial supply.
Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO) and biosafety testing provider, has announced an expanded manufacturing partnership with Genetix Biotherapeutics Inc. to increase commercial-scale production of LYFGENIA. The therapy is approved by the US Food and Drug Administration as a one-time gene therapy for individuals aged 12 years and older with sickle cell disease.
The expansion is intended to increase manufacturing capacity to meet growing commercial demand while maintaining quality, consistency, and regulatory requirements associated with commercial CGT manufacturing. The collaboration builds on an existing relationship between the two companies and is focused on supporting sustained commercial supply as demand increases.
To support the expansion, Minaris Advanced Therapies has implemented process and operational improvements designed to increase manufacturing efficiency, reduce turnaround times, and significantly raise output. The company has also continued to invest in infrastructure, talent, and capacity to support long-term commercial supply without disruption.
“Our focus is on investing early, building efficiency into the process, and ensuring our partners have the capacity and cost structure to scale as patient needs grow.”
Dr. Eytan Abraham, Chief Commercial & Technology Officer at Minaris
The companies said the collaboration supports Minaris’ broader role in helping advanced therapy developers transition from development into sustained commercial production. The expanded capacity is intended to support Genetix’s commercial growth while maintaining operational standards expected in regulated CDMO and contract manufacturing environments.
